Viking's oral weight loss candidate VK2735 has moved into late-stage testing, putting another pill in the race against Lilly and Novo.
Recap by typeshit. Post by @cgxpwire on Instagram.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Miami Herald looks at how oral peptide drugs are designed to get past the gut intact and reach specific targets in the body.
Futurism reports deaths tied to unapproved retatrutide sold outside legal channels, as gray-market demand for the drug keeps growing.
Loading…